Clinical Trials Logo

Gut Microbiota clinical trials

View clinical trials related to Gut Microbiota.

Filter by:

NCT ID: NCT05290519 Recruiting - Inflammation Clinical Trials

Comparison of Plant-based or Animal-based Protein on Anthropocentric and Metabolic Parameters in Obese Subjects

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The investigators will try to evaluate the effects of substitution of dietary animal protein by black soybean milk (400 mL x 2) per day on anthropocentric and metabolic parameters in obese subjects.

NCT ID: NCT05205187 Recruiting - Stomach Neoplasms Clinical Trials

Gut Microbiota and Metabonomics

MBS
Start date: February 28, 2022
Phase:
Study type: Observational [Patient Registry]

To evaluate the correlation between gut microbiota and metabolites in Borrmann type IV gastric cancer; To find the effects of microflora and metabolites on target organs; To detect the mechanism of key flora and metabolite by in vitro and in vivo experiments; To construct models of gut microbiota and metabonomics by machine learning.

NCT ID: NCT05178524 Completed - Clinical trials for Hepatocellular Carcinoma

Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

On the basis of previous studies, this study intends to explore the effect of BIFICO on liver function recovery of patients with hepatocellular carcinoma (HCC) after surgery, so as to provide a new method for accelerating liver function recovery of HCC patients during perioperative period. This project is an open, randomized, blank-controlled clinical study. Liver resection patients were randomly divided into two groups, one group received continuous administration of BIFICO during perioperative period, and the dosage was controlled according to the instructions. The other group was a blank control. Stool samples were collected at three time points (before medication, before and after surgery) in two groups. Statistical analysis was performed to compare the differences of postoperative liver function and preoperative and postoperative gut microbiota between the two groups. Through this study, the investigators aimed to verify the beneficial changes of intestinal microflora in HCC patients with BIFICO during perioperative period .

NCT ID: NCT05123352 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies

Start date: November 2021
Phase:
Study type: Observational

In this observational single-center cohort study, metagenomic Next-Generation Sequencing (mNGS) will be used to investigate the features and changes of gut microbiota in acute myeloid leukemia (AML) patients during the treatment of two different induction therapy regimens [standard intensive chemotherapy (7+3) or bcl-2 inhibitor-based targeted therapy].

NCT ID: NCT05086458 Recruiting - Gut Microbiota Clinical Trials

Impact of Probiotics Supplement on the Gut Microbiota in Caesarean-born Infants

Start date: August 17, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of probiotics on the gut microbiota of infants born by cesarean section.

NCT ID: NCT05065515 Recruiting - Gut Microbiota Clinical Trials

Establishment of Individualized Immunotherapy Strategy and Platform Based on Changes of Intestinal Microbiota

Start date: October 1, 2021
Phase:
Study type: Observational

To explore and analyze the relationship between intestinal flora changes and the efficacy of individualized immunotherapy in patients with upper gastrointestinal cancer, and to find new biomarkers to predict the efficacy of immunotherapy, bringing new breakthroughs in tumor diagnosis and treatment.

NCT ID: NCT05057039 Enrolling by invitation - Hypertension Clinical Trials

The Study of Gut Microbiota in Hypertensive Patients

Start date: September 1, 2021
Phase:
Study type: Observational

Recent animal and human studies have found the relationship between the composition of the gut microbiota and hypertension, but some studies did not have a detailed evaluation of the diet content, which could be an important effect on gut microbiota. Moreover, most of these studies were finished in Western countries, in which the dietary patterns were significantly different from those in Chinese regions. This study intends to establish Taiwanese local data to explore the differences in the composition of gut microbiota among hypertensive patients and normotensive subjects.

NCT ID: NCT05039060 Not yet recruiting - Colorectal Cancer Clinical Trials

Modified MAC Diet and Gut Microbiota in CRC Patients

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

To explore the changes in the composition and diversity of intestinal microbiota during 3-weeks of modified MAC diet and conventional diet in stage I or low-risk stage II colorectal cancer (CRC) patients after surgery. Additionally, the investigator analyze the association of gut microbiota and stool formation pattern or quality of life according to dietary pattern. Therefore, the investigator identify the beneficial or harmful microbiota composition and diversity adapting modified MAC diet that related to cancer recurrence, which provide supporting evidence for future prospective trial.

NCT ID: NCT05016752 Recruiting - Clinical trials for Acute Myeloid Leukemia

Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infection

Start date: August 5, 2021
Phase:
Study type: Observational

Acute myeloid leukemia (AML) patients are prone to blood stream infection (BSI) due to bone marrow suppression, oral and gastrointestinal mucositis, endovascular tubes, and the application of a large number of broad-spectrum antibiotics. The associated mortality rate is as high as 7.1 %-42%. The use of antibiotics within one hour after the first observation of hypotensive symptoms can guarantee a 79.9% survival rate. For every hour of delay, the patient's survival rate will drop by 7.6%. At present, the blood culture test cycle is long and the positive rate is low. Other infection-related indicators (PCT, CRP) or next-generation sequencing are not highly specific and easy to be misdiagnosed. X-ray, CT and other examinations only have a certain auxiliary value for the infected site. We need new diagnostic tools to accurately identify pathogens. Nano-seq is a next-generation sequencing technology for single-molecule, real-time sequencing and analysis. With ultra-long sequencing read length, it can quickly and accurately identify BSI pathogens types, and give appropriate drug sensitivity results based on drug resistance genes to meet the needs of 99.9% pathogen screening. At the same time, we hope to conduct a prospective evaluation to target high-risk groups of AML prone to BSI in the early stage. The intestine is the body's largest immune organ and the largest reservoir of microbial pathogens. The expansion of certain gut microbiota usually precedes BSI. If there is a correlation between the gut microbiota and MDR-BSI, the colonization and changes of the intestinal flora can be used to predict the risk of BSI in patients during treatment, and preventive measures such as early decolonization or biological intervention will reduce the risk of infection in the future. Combined with Nano-seq and various existing clinical pathogen detection technologies to reduce the occurrence and progress of clinical BSI.

NCT ID: NCT05008120 Recruiting - Gut Microbiota Clinical Trials

Gut Microbiota in Major Depressive Disorders With and Without Rapid Eye Movement Behavior Disorder

Start date: October 1, 2021
Phase:
Study type: Observational

The purpose of this study is to identify the variations in gut microbiota compositions between two subtypes of major depressive disorder.